[1] S. M. Haffner, “Abdominal adiposity and cardiometabolic risk: do we have all the answers?” American Journal of Medicine, vol. 120, no. 9, pp. S10–S16, 2007.
[2] G. Posern and R. Treisman, “Actin’ together: serum response factor, its cofactors and the link to signal transduction,” Trends in Cell Biology, vol. 16, no. 11, pp. 588–596, 2006.
[3] G. C. T. Pipes, E. E. Creemers, and E. N. Olson, “The myocardin family of transcriptional coactivators: versatile regulators of cell growth, migration, and myogenesis,” Genes and Development, vol. 20, no. 12, pp. 1545–1556, 2006.
[4] X. Zhang, G. Azhar, J. Chai et al., “Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 280, no. 4, pp. H1782–H1792, 2001.
[5] A. Parlakian, C. Charvet, B. Escoubet et al., “Temporally controlled onset of dilated cardiomyopathy through disruption of the srf gene in adult heart,” Circulation, vol. 112, no. 19, pp. 2930–2939, 2005.
[6] X. Zhang, G. Azhar, M. C. Furr, Y. Zhong, and J. Y. Wei, “Model of functional cardiac aging: young adult mice with mild overexpression of serum response factor,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 285, no. 3, pp. R552–R560, 2003.
[7] G. Azhar, X. Zhang, S. Wang, Y. Zhong, C. M. Quick, and J. Y. Wei, “Maintaining serum response factor activity in the older heart equal to that of the young adult is associated with better cardiac response to isoproterenol stress,” Basic Research in Cardiology, vol. 102, no. 3, pp. 233–244, 2007.
[8] J. M. Miano, “Role of serum response factor in the pathogenesis of disease,” Laboratory Investigation, vol. 90, no. 9, pp. 1274–1284, 2010.
[9] N. Halberg, I. Wernstedt-Asterholm, and P. E. Scherer, “The adipocyte as an endocrine cell,” Endocrinology and Metabolism Clinics of North America, vol. 37, no. 3, pp. 753–768, 2008.
[10] J.-Y. Kim, E. van de Wall, M. Laplante et al., “Obesity- associated improvements in metabolic profile through expan- sion of adipose tissue,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2621–2637, 2007.
[11] R. J. Deckelbaum, T. S. Worgall, and T. Seo, “n-3 fatty acids and gene expression,” American Journal of Clinical Nutrition, vol. 83, no. 6, p. 1520S, 2006.
[12] S. Neschen, K. Morino, J. C. Rossbacher et al., “Fish oil regulates adiponectin secretion by a peroxisome proliferator- activated receptor-γ-dependent mechanism in mice,” Diabetes, vol. 55, no. 4, pp. 924–928, 2006.
[13] A. Banga, R. Unal, P. Tripathi et al., “Adiponectin translation is increased by the PPARγ agonists pioglitazone and ω-3 fatty acids,” American Journal of Physiology—Endocrinology and Metabolism, vol. 296, no. 3, pp. E480–E489, 2009.
[14] M. Rodbell, “Metabolism of isolated fat cells. I. Effects of hormone on glucose metabolism and lipolysis,” Journal of Biological Chemistry, vol. 239, pp. 375–380, 1964.
[15] B. Saffari, J. M. Ong, and P. A. Kern, “Regulation of adipose tissue lipoprotein lipase gene expression by thyroid hormone in rats,” Journal of Lipid Research, vol. 33, no. 2, pp. 241–249, 1992.
[16] H. Green and M. Meuth, “An established pre adipose cell line and its differentiation in culture,” Cell, vol. 3, no. 2, pp. 127– 133, 1974.
[17] J. Chang, L. Wei, T. Otani, K. A. Youker, M. L. Entman, and R. J. Schwartz, “Inhibitory cardiac transcription factor, SRF-N, is generated by caspase 3 cleavage in human heart failure and attenuated by ventricular unloading,” Circulation, vol. 108, no. 4, pp. 407–413, 2003.
[18] U. B. Pajvani, X. Du, T. P. Combs et al., “Structure- function studies of the adipocyte-secreted hormone Acrp30/adiponectin: implications for metabolic regulation and bioactivity,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9073–9085, 2003.
[19] R. Unal, A. Yao-Borengasser, V. Varma et al., “Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2993–3001, 2010.
[20] M. Itoh, T. Suganami, N. Satoh et al., “Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 9, pp. 1918– 1925, 2007.
[21] N. Rasouli, A. Yao-Borengasser, L. M. Miles, S. C. Elbein, and P. A. Kern, “Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression,” American Journal of Physiology—Endocrinology and Metabolism, vol. 290, no. 1, pp. E42–E46, 2006.
[22] A. M. Bodles, A. Banga, N. Rasouli, F. Ono, P. A. Kern, and R. J. Owens, “Pioglitazone increases secretion of high-molecular- weight adiponectin from adipocytes,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 5, pp. E1100–E1105, 2006.
[23] F. Abbasi, J. W. Chu, C. Lamendola et al., “Discrimination between obesity and insulin resistance in the relationship with adiponectin,” Diabetes, vol. 53, no. 3, pp. 585–590, 2004.
[24] L. Tao, E. Gao, X. Jiao et al., “Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress,” Circulation, vol. 115, no. 11, pp. 1408–1416, 2007.
[25] C. Gauthier-Rouviere, M. Vandromme, D. Tuil et al., “Expres- sion and activity of serum response factor is required for expression of the muscle-determining factor MyoD in both dividing and differentiating mouse C2C12 myoblasts,” Molec- ular Biology of the Cell, vol. 7, no. 5, pp. 719–729, 1996.
[26] K. Sakuma, M. Akiho, H. Nakashima, H. Akima, and M. Yasuhara, “Age-related reductions in expression of serum response factor and myocardin-related transcription factor A in mouse skeletal muscles,” Biochimica et Biophysica Acta, vol. 1782, no. 7-8, pp. 453–461, 2008.
[27] J. Bełtowski, A. Jamroz-Wiśniewska, and S. Widomska, “Adiponectin and its role in cardiovascular diseases,” Cardio- vascular and Hematological Disorders—Drug Targets, vol. 8, no. 1, pp. 7–46, 2008.
[28] T. Inoue, N. Kotooka, T. Morooka et al., “High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease,” American Journal of Cardiology, vol. 100, no. 4, pp. 569–574, 2007.
[29] B. B. Duncan, M. I. Schmidt, J. S. Pankow et al., “Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study,” Diabetes, vol. 53, no. 9, pp. 2473– 2478, 2004.
[30] R. C. Valentine and D. L. Valentine, “Omega-3 fatty acids in cellular membranes: a unified concept,” Progress in Lipid Research, vol. 43, no. 5, pp. 383–402, 2004.
[31] R. Shibata, K. Sato, D. R. Pimentel et al., “Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms,” Nature Medicine, vol. 11, no. 10, pp. 1096–1103, 2005.